Taprizosin

• Description:

  Taprizosin (UK-338003) is an α-adrenoreceptor antagonist[1].

• Product Name Alternative:

  UK-338003

• UNSPSC:

  12352005

• Target:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cardiovascular Disease; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/taprizosin.html

• Smiles:

  CS(=O)(NC1=CC=CC2=C1CCN(C3=NC(N)=C4C(C5=NC=CC=C5)=C(OC)C(OC)=CC4=N3)C2)=O

• Molecular Formula:

  C25H26N6O4S

• Molecular Weight:

  506.58

• References & Citations:

  [1]Collett A, et al. Investigation of regional mechanisms responsible for poor oral absorption in humans of a modified release preparation of the alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2- (5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl) -5- (2-pyridyl) quinazoline (UK-338,003) : the rational use of ex vivo intestine to predict in vivo absorption. Drug Metab Dispos. 2008 Jan;36 (1) :87-94.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  210538-44-6